Abstract:Objective: The objective of the current study was to create a pyrazole scaffold derivation that could be used as a medication to treat specific protein and gene alterations without causing harm to healthy cells. Methods: Focusing on this class of compounds, we report an efficient synthesis of substituted bipyrazole derivative and structural characterizations have been carried out including spectroscopic (FTIR, 1H NMR, 13C NMR, and MS) and physiochemical methods. The newly synthesized derivative was evaluated for their anti-proliferative activity against sixty cancer cell lines at the (NCI/USA) for the one and five-dose assay. Additionally, kinase profiling evaluation was used to screen for further exploration of its putative anticancer pathways. For the target compound, additional ADMET studies were carried out. Results: The acquired data demonstrated a potent effect against nearly the full panel giving GI50 (MG-MID: 3.59 μM). Also, liver of the DENA-rats treated with this product exhibited a remarkable improvement in the hepatic configuration with no marked acute toxicity and normalization of all liver parameters including AST, ALT, and ALP activities and the total bilirubin level. Also, the data indicated that the target compound could exert its cytotxic activity through dual-targeted kinase inhibitory potency against VEGFR-2 and CDK-2/cyclin A2 with (IC50 = 3.37 ± 1.00 and 0.73 ± 0.22 μM, respectively) relating with the references sorafenib and roscovitine (IC50 = 1.60 ± 0.10 and 0.68 ± 1.10 μM, respectively). ADMET studies, demonstrating its good drug-like characteristics and reduced toxicity. Conclusions: This work offers a very effective new molecule that may serve as an excellent starting point for the development of prospective anti-tumor drugs for additional preclinical research.

Structure-based Design and Synthesis of Imidazo[1,2-A]pyridine Derivatives As Novel and Potent Nek2 Inhibitors with in Vitro and in Vivo Antitumor Activities

Design, Synthesis, and Structure Activity Relationship (SAR) Studies of Novel Imidazo[1,2-A] Pyridine Derivatives As Nek2 Inhibitors

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Design, Synthesis, Antitumor Activity Evaluation, and Molecular Dynamics Simulation of Some 2-Aminopyrazine Derivatives

New Application of Novel Tetrazine Derivatives As Potent VEGFR-2 Kinase Inhibitors and Anti-Cancer Agents

Design, Synthesis, Anticancer Evaluation and In Silico Studies of Imidazole Pyrazine Compounds

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.

Design, Synthesis, Biological Evaluation of Benzoyl Amide Derivatives Containing Nitrogen Heterocyclic Ring As Potential VEGFR-2 Inhibitors

Design, Synthesis and Anticancer Activity of a New Series of N-aryl-N′-[4-(pyridin-2-ylmethoxy)benzyl]urea Derivatives

Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.

Structure–activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy

Synthesis and Cytotoxic Activity of Some Novel N-Pyridinyl-2-(6-phenylimidazo[2,1-b]thiazol-3-yl)acetamide Derivatives

Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Synthesis and Antitumor Activity of Novel 2, 3-Didithiocarbamate Substituted Naphthoquinones As Inhibitors of Pyruvate Kinase M2 Isoform.

Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-B]pyridazine Derivatives As Mtor Inhibitors

Design, Synthesis and Anticancer evaluation of Imamine-1,3,5-triazine derivatives

Novel Bipyrazole Targeting Dual CDK-2 and VEGFR-2 Kinases: Synthesis, Anticancer Evaluation, and In Silico Studies

Design of Novel Imidazopyrazine Derivative against Breast Cancer via Targeted NPY1R Antagonist

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists.